PF-04621053

PF-04621053 is a selective small molecule inhibitor of the voltage-gated sodium channel Nav1.7 (SCN9A), developed by Pfizer for the treatment of pain. Nav1.7 is a critical transducer of pain signals in the peripheral nervous system, and its selective inhibition was hypothesized to provide potent analgesia without the dose-limiting central nervous system and cardiovascular side effects associated with non-selective sodium channel blockers. PF-04621053 was evaluated in Phase 2 clinical trials for indications including post-herpetic neuralgia and acute dental pain. However, the clinical program was terminated after the compound failed to demonstrate a statistically significant reduction in pain scores compared to placebo, reflecting the broader challenges in translating Nav1.7 inhibition into clinical efficacy.